(CNMD) CONMED - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 1.121m USD | Total Return: -37.1% in 12m
Avg Turnover: 14.7M
EPS Trend: 84.5%
Qual. Beats: 0
Rev. Trend: 94.9%
Qual. Beats: 4
Warnings
Fakeout Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
CONMED Corporation (NYSE: CNMD) is a medical technology firm specializing in surgical devices and equipment across three primary categories: orthopedics, general surgery, and endoscopic technologies. The company’s portfolio includes advanced soft tissue fixation systems, clinical insufflation systems under the AirSeal brand, and electrosurgical generators. CONMED operates within the medical device sector, which often relies on a razor-and-blade business model where the sale of capital equipment drives recurring revenue through high-volume, single-use surgical consumables.
The company distributes its products to hospitals and ambulatory surgery centers through both a direct sales force and specialty medical distributors. This sub-industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for significant research and development to maintain clinical differentiation. For a deeper look into these financial metrics, ValueRay offers additional data points. Investors should note that CONMED’s growth is historically tied to the global volume of minimally invasive procedures across orthopedic and gastroenterology specialties.
- AirSeal and Buffalo Filter adoption drives high-margin general surgery revenue growth
- BioBrace product expansion accelerates penetration into the orthopedic soft tissue market
- Hospital capital expenditure cycles influence demand for Hall surgical power tools
- Supply chain stability and manufacturing costs impact overall gross profit margins
- Electrosurgery and endoscopic technology sales depend on elective surgical procedure volumes
| Net Income: 54.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.82 > 1.0 |
| NWC/Revenue: 27.54% < 20% (prev 27.08%; Δ 0.46% < -1%) |
| CFO/TA 0.06 > 3% & CFO 142.6m > Net Income 54.8m |
| Net Debt (848.6m) to EBITDA (211.4m): 4.01 < 3 |
| Current Ratio: 2.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.6m) vs 12m ago -1.70% < -2% |
| Gross Margin: 53.58% > 18% (prev 0.55%; Δ 5.30k% > 0.5%) |
| Asset Turnover: 59.49% > 50% (prev 57.19%; Δ 2.30% > 0%) |
| Interest Coverage Ratio: 5.14 > 6 (EBITDA TTM 211.4m / Interest Expense TTM 29.9m) |
| A: 0.16 (Total Current Assets 670.6m - Total Current Liabilities 292.7m) / Total Assets 2.31b |
| B: 0.26 (Retained Earnings 602.6m / Total Assets 2.31b) |
| C: 0.07 (EBIT TTM 153.4m / Avg Total Assets 2.31b) |
| D: 0.43 (Book Value of Equity 558.2m / Total Liabilities 1.30b) |
| Altman-Z'' = 2.82 = A |
| DSRI: 0.99 (Receivables 228.7m/221.1m, Revenue 1.37b/1.31b) |
| GMI: 1.04 (GM 53.58% / 55.47%) |
| AQI: 0.99 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.04 (Revenue 1.37b / 1.31b) |
| TATA: -0.04 (NI 54.8m - CFO 142.6m) / TA 2.31b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 36.06 with a total of 344,200 shares traded.
Over the past week, the price has changed by -1.50%,
over one month by -4.78%,
over three months by -21.39% and
over the past year by -37.13%.
CONMED has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CNMD.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.6 | 9.8% |
P/E Trailing = 21.0339
P/E Forward = 27.1739
P/S = 0.8179
P/B = 1.0953
P/EG = 1.8437
Revenue TTM = 1.37b USD
EBIT TTM = 153.4m USD
EBITDA TTM = 211.4m USD
Long Term Debt = 860.2m USD (from longTermDebt, last quarter)
Short Term Debt = 711k USD (from shortTermDebt, last quarter)
Debt = 883.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.8m
Net Debt = 848.6m USD (calculated: Debt 883.7m - CCE 35.0m)
Enterprise Value = 1.97b USD (1.12b + Debt 883.7m - CCE 35.0m)
Interest Coverage Ratio = 5.14 (Ebit TTM 153.4m / Interest Expense TTM 29.9m)
EV/FCF = 15.92x (Enterprise Value 1.97b / FCF TTM 123.7m)
FCF Yield = 6.28% (FCF TTM 123.7m / Enterprise Value 1.97b)
FCF Margin = 9.02% (FCF TTM 123.7m / Revenue TTM 1.37b)
Net Margin = 4.00% (Net Income TTM 54.8m / Revenue TTM 1.37b)
Gross Margin = 53.58% ((Revenue TTM 1.37b - Cost of Revenue TTM 636.9m) / Revenue TTM)
Gross Margin QoQ = 57.86% (prev 57.12%)
Tobins Q-Ratio = 0.85 (Enterprise Value 1.97b / Total Assets 2.31b)
Interest Expense / Debt = 3.38% (Interest Expense 29.9m / Debt 883.7m)
Taxrate = 24.66% (4.53m / 18.4m)
NOPAT = 115.6m (EBIT 153.4m * (1 - 24.66%))
Current Ratio = 2.29 (Total Current Assets 670.6m / Total Current Liabilities 292.7m)
Debt / Equity = 0.87 (Debt 883.7m / totalStockholderEquity, last quarter 1.02b)
Debt / EBITDA = 4.01 (Net Debt 848.6m / EBITDA 211.4m)
Debt / FCF = 6.86 (Net Debt 848.6m / FCF TTM 123.7m)
Total Stockholder Equity = 1.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 54.8m / Total Assets 2.31b)
RoE = 5.40% (Net Income TTM 54.8m / Total Stockholder Equity 1.02b)
RoCE = 8.18% (EBIT 153.4m / Capital Employed (Equity 1.02b + L.T.Debt 860.2m))
RoIC = 5.81% (NOPAT 115.6m / Invested Capital 1.99b)
WACC = 6.52% (E(1.12b)/V(2.00b) * Re(9.66%) + D(883.7m)/V(2.00b) * Rd(3.38%) * (1-Tc(0.25)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -44.72 | Cagr: -1.40%
[DCF] Terminal Value 73.10% ; FCFF base≈140.0m ; Y1≈122.8m ; Y5≈99.2m
[DCF] Fair Price = 24.71 (EV 1.59b - Net Debt 848.6m = Equity 744.1m / Shares 30.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 84.50 | EPS CAGR: 15.66% | SUE: 0.56 | # QB: 0
Revenue Correlation: 94.94 | Revenue CAGR: 6.36% | SUE: 2.24 | # QB: 4
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=+1.40% | Revisions=+33% | Analysts=6
EPS next Quarter (2026-09-30): EPS=1.05 | Chg30d=-0.12% | Revisions=+14% | Analysts=6
EPS current Year (2026-12-31): EPS=4.37 | Chg30d=+0.42% | Revisions=+40% | GrowthEPS=-4.7% | GrowthRev=-0.9%
EPS next Year (2027-12-31): EPS=4.85 | Chg30d=-1.63% | Revisions=-56% | GrowthEPS=+10.8% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -56%